Position in ANVS
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$52,081
+$14,169 QoQ
Shares Held
28,001
+64.7% QoQ
Ownership
0.066%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#24
of 61 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CWA Asset Management Group, LLC holds $28,091,999 across 13 Biotechnology names. ANVS ranks #12 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
83,249 | $9,437,106 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
19,619 | $4,727,590 | |
| 3 | EXEL |
Exelixis, Inc.
|
63,173 | $3,437,242 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
|
202,440 | $3,435,406 | |
| 5 | TBPH |
Theravance Biopharma, Inc.
|
134,994 | $2,294,898 | |
| 6 | HRMY |
Harmony Biosciences Holdings, Inc.
|
61,273 | $2,230,949 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,623 | $1,012,005 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
10,500 | $821,835 |
All Filings in ANVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $52,081 | 28,001 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $37,912 | 17,001 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $58,823 | 17,001 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $26,912 | 13,001 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $41,232 | 19,001 | Shares | Sole | 2025-07-17 | |
| No filing history on record for this holder in this stock. | ||||||